

Determination of Peramivir and Its Toxicokinetics in Beagle Dogs

by

Yang Jing



Institute of Chinese Medical Sciences

University of Macau

**Determination of Peramivir and Its
Toxicokinetics in Beagle Dogs**

By

Yang Jing

A thesis submitted in partial fulfillment of the
requirements for the degree of

Master of Science

Institute of Chinese Medical Sciences
University of Macau

2010



Approved by _____ Supervisor

Date _____

In presenting this thesis in partial fulfillment of the requirements for a Master's degree at the University of Macau, I agree that the Library and the Institute of Chinese Medical Sciences shall make its copies freely available for inspection. However, reproduction of this thesis for any purposes or by any means shall not be allowed without my written permission. Authorization is sought by contacting the author at

Address:

Telephone:

Fax:

E-mail:



碩士學位論文

測定 Beagle 犬體內的帕拉米韋 及其毒代動力學研究

UNIVERSIDADE DE MACAU

研究生姓名： 楊 靜

導 師： 李紹平

專 業： 中 藥 學

日 期： 2011.7

澳門大學



澳門大學中華醫藥研究院

ACKNOWLEDGMENTS

I would like to express my deepest gratitude to my supervisor, Prof. Shaoping Li. I am strongly inspired by your stringent realistic attitude, dedication and assiduous work style and innovation spirit. You have given me enlightenment, guidance and inexhaustible patience throughout my study. I could not do the work well without your steady support.

Especially, sincere thanks to Director of Institute of Chinese Medical Sciences (ICMS), Prof. Yitao Wang, for his kindness and providing me the precious opportunity to accumulate speculative knowledge and improve experimental skills which is significantly important for my whole life.

I also owe my sincere thanks to Dr. Qingwen Zhang, Prof. Simon Lee, Dr. Ying Zheng, Dr. Ru Yan, Dr. Maggie Hoi, Ms. Hattie U and Ms. Chloe Lao for the support during the learning and living.

This research work was supported by all members of ICMS, University of Macau. Special thanks to Leon Lai for technical supports.

Thanks to Jing Zhao, Deqiang Li and Siokio Kuong for their guidance on experiment and thesis writing. Thanks to Jia Guan, Xiaojia Chen, Kun Feng, Zhengming Qian, Weihua Huang, Jing Li and Lanzhen Meng for their help on my experiments.

Thanks to Dejun Hu, Guangping Lv, Xu Jun and Qiong Meng for offering me help during these study years, and giving me the great happiness impressed in my memory forever.

Thanks to my family for offering me great support all the time.

University of Macau

ABSTRACT

DETERMINATION OF PERAMIVIR AND ITS TOXICOKINETICS IN BEAGLE DOGS

by Yang Jing

Thesis Supervisor: Professor Li Shaoping

Major: Chinese Medicinal Sciences

Peramivir as a new potent neuraminidase inhibitor was reported effectively inhibition of both influenza A and influenza B virus and also considered as a therapy for the influenza pandemic, such as H1N1, H5N1 and H3N2. *In vitro* and *in vivo* pharmacodynamics results show that peramivir is comparable or better than other two licensed neuraminidase inhibitors, oseltamivir carboxylate and zanamivir. Therefore peramivir was considered as a potent new drug for treatment of influenza. For drug registration, toxicokinetic analysis has generally been requested as a routine component of toxicological evaluation and safety assessment. This paper studies on the concomitant toxicokinetics of peramivir in beagle dog and provide useful information for its clinical safety trials.

The thesis consists of two chapters. **Chapter 1** is the introduction of the thesis including the pandemic hazard of influenza virus as well as its treatment, and the current progress of peramivir. In **Chapter 2**, a 30-day concomitant toxicokinetics study of peramivir in beagle dogs was carried out as part of the preclinical safety profile. Three groups of four dogs per gender were intravenously administrated once daily at three dose levels of 77.8, 233.3 and 700.0 mg/kg. Plasma samples were collected on two periods (1st day and 30th day). Reverse-phase HPLC method with 210 nm UV detection was established to determine the concentration of peramivir in plasma. Good inter/intra-batch precision (<9.1%) and recoveries (> 82.5%) on low-, mid-, and high-level were obtained. The toxicokinetic analysis was performed with

WinNonlin 5.2. C_{\max} and AUC increased with increment of dose. At 77.8, 233.3 and 700.0 mg/kg, AUC_{0-24} were 301.3 ± 45.8 , 939.6 ± 275.5 , 5445.9 ± 956.7 mg*hr/L and 293.0 ± 40.6 , 993.5 ± 165.6 , 4180.8 ± 1102.0 mg*hr/L on 1st day and 30th day, respectively; There was no statistic significant difference in $MRT_{0-\infty}$ among different doses or between the two collecting terms.

Key words: *peramivir; toxicokinetics; influenza; neuraminidase inhibitor; beagle dog*



摘要

測定 Beagle 犬體內的帕拉米韋 及其毒代動力學研究

碩士生：楊靜

導師：李紹平 教授

專業：中藥學

帕拉米韋作為強有效的神經氨酸酶抑制劑能有效抑制流感病毒A和B而被認為可以控制諸如H1N1, H5N1及H3N2等病毒引起的流感傳播。體內及體外藥效學實驗顯示帕拉米韋的藥效至少不低於其他兩種臨床神經氨酸酶抑制劑：奧司他韋和紮那米韋。因此帕拉米韋被視為相當有潛力的新藥。在新藥註冊過程中毒代動力學分析是毒性評定和藥物安全評估中必不可少的部分。而本實驗為帕拉米韋在Beagle犬體內的毒代動力學研究並為臨床安全評價提供依據。

本論文包括兩章：第一章是綜述部分，包括：流感病毒的流行性危害及治療手段，和抗流感病毒藥帕拉米韋的研究進展。第二章為帕拉米韋 Beagle犬靜脈滴注反復給藥（一個月）毒性試驗的伴隨試驗。將24只健康Beagle犬隨機分成三組分別按劑量77.8 mg/kg、233.3 mg/kg和700.0 mg/kg靜脈滴注帕拉米韋，每天給藥一次，連續給藥一個月，分別於兩個週期即給藥第1天和第30天采血，採用HPLC-UV法測定帕拉米韋血藥濃度。該方法高、中、低三個濃度批間和批內變異（RSD）均小於10%；提取回收率>82%，顯示了良好的適用性。採用WinNonlin 5.2進行毒代動力學資料分析發現AUC與劑量成正相關：給藥第1天，低、中、高三個劑量組帕拉米韋AUC₀₋₂₄分別為301.3±45.8 mg*hr/L、939.6±275.5 mg*hr/L和5445.9±956.7 mg*hr/L，第30天，AUC₀₋₂₄分別為293.0±40.6 mg*hr/L、993.5±165.6 mg*hr/L和4180.8±1102.0 mg*hr/L。相同給藥週期（第1天或第30天）不同劑量組和不同給藥週期（第1天和第30天）相同劑量組相比較，帕拉米韋平均駐留時間（MRT_{0-∞}）均無顯著性差異。

關鍵詞：帕拉米韋；毒代動力學；流行性感冒；神經氨酸酶抑制劑；Beagle犬

TABLE OF CONTENTS

Chapter 1: Influenza and anti-influenza reagents	4
1. Current research on influenza	4
1.1 Pandemic hazard of influenza virus	4
1.2 Treatment of influenza	6
2. The progress research of peramivir.....	11
2.1 Development of peramivir	11
2.2 Pharmacokinetics studies of peramivir	11
2.3 Pharmacodynamic studies of peramivir.....	13
Chapter 2: Toxicokinetics of peramivir in beagle dogs	18
1. Materials and methods	18
1.1 Chemicals.....	18
1.2 Apparatus	18
1.3 Animals and experiment design.....	19
1.4 Preparation of stock solution	19
1.5 Preparation of plasma samples for toxicokinetic studies.....	20
1.6 HPLC-UV method	20
2. Results and discussion	20
2.1 Method optimization.....	20
2.2 Method validation	24
2.3 Routine calibration and quality control samples	41
2.4 Plasma concentration-time curve of peramivir for beagle dogs following intravenous administration.....	45
2.5 Parameters calculation.....	59
2.6 Statistics analysis.....	60
2.7 Toxicokinetics.....	62
3. Conclusion	65
References	66

LIST of Abbreviations

Abbreviations	Full Name
HA	Haemagglutinin
NA	Neuraminidase
M2	Matrix 2
NANA	<i>N</i> -acetylneuraminic acid
DANA	2-deoxy-2,3-didehydro- <i>N</i> -acetylneuraminic acid
T 705	Pyrazine
IMP	Inosine 5'-monophosphate
Neu5ac2en	Neuraminic acid
AUC	The area under the plasma concentration-time curve
C _{max}	Maximum concentration in plasma
MRT	Mean residence time
CPE	Cytopathic effect
UV	Ultra violet
MS	Mass spectrum
IM	Intramuscular
FDA	Food and Drug Administration
EUA	Emergency Use Authorization
LLOQ	Lower limit of quantification
ULOQ	Upper limit of quantification
QC samples	Quality control samples
i.v.	Intravenous

LIST OF TABLES

Table 1.1 Inhibition of the influenza viruses by peramivir, oseltamivir and zanamivir	14
Table 2.1 Linear regression of peramivir in beagle dog plasma(Test 1).....	32
Table 2.2 Linear regression of peramivir in beagle dog plasma(Test 2).....	32
Table 2.3 Linear regression of peramivir in beagle dog plasma(Test 3).....	32
Table 2.4 Linear regression of peramivir in beagle dog plasma(Test 4).....	33
Table 2.5 Summary of accuracy and precision of LLOQ	33
Table 2.6 Validation of increased sample volume.....	34
Table 2.7 Dilution validation	35
Table 2.8 Recovery and matrix effect for peramivir.....	36
Table 2.9 Precision and accuracy of peramivir.....	37
Table 2.10 Stability of peramivir solution at 4 °C.....	38
Table 2.11 Stability of peramivir solution at room temperature	38
Table 2.12 Stability of peramivir in plasma.....	40
Table 2.13 Linear regression of peramivir assay in plasma (first batch).....	41
Table 2.14 Quality control samples for peramivir assay in plasma (first batch)	42
Table 2.15 Linear regression of peramivir assay in plasma (second batch)	42
Table 2.16 Quality control samples for peramivir assay in plasma (second batch).	43
Table 2.17 Linear regression of peramivir assay in plasma (third batch).....	43
Table 2.18 Quality control samples for peramivir assay in plasma (third batch)	44
Table 2.19 Linear regression of peramivir assay in plasma (fourth batch).....	44
Table 2.20 Quality control samples for peramivir assay in plasma (fourth batch) ..	45
Table 2.21 Plasma concentration ($\mu\text{g/mL}$) of peramivir in beagle dogs after intravenous drip of 77.8 mg/kg (The first day).....	46
Table 2.22 Plasma concentration ($\mu\text{g/mL}$) of peramivir in beagle dogs after intravenous drip of 233.3 mg/kg (The first day).....	47
Table 2.23 Plasma concentration ($\mu\text{g/mL}$) of peramivir in beagle dogs after	

intravenous drip of 700.0 mg/kg (The first day).....	48
Table2.24 Plasma concentration ($\mu\text{g/mL}$) of peramivir in beagle dogs after intravenous drip of 77.8 mg/kg (The 30th day)	49
Table2.25 Plasma concentration ($\mu\text{g/mL}$) of peramivir in beagle dogs after intravenous drip of 233.3 mg/kg (The 30th day)	50
Table2.26 Plasma concentration ($\mu\text{g/mL}$) of peramivir in beagle dogs after intravenous drip of 700.0 mg/kg (The 30th day)	51
Table2.27 Toxicokinetics parameters after i.v. drip to beagle dogs	60
Table2.28 Statistic results of toxicokinetics parameters in Beagle dogs	61



LIST OF FIGURES

Figure 1.1 Different types of antivirus agents based on molecular target of interaction	7
Figure 1.2 Typical examples for major classes of anti-virus agents	8
Figure 2.1 HPLC-UV profile of the peramivir standard solution and blank plasma on HILIC column.....	22
Figure 2.2 HPLC-UV profile of peramivir plasma at different PH values	23
Figure 2.3 HPLC-UV profile of blank plasma from six different sources	26
Figure 2.4 HPLC-UV profile of blank plasma from six different sources with peramivir	29
Figure 2.5 HPLC-UV profile of plasma from Beagle dog (F03) after intravenous dripped of peramivir (233.3 mg/kg) for 8 hours on the first day.....	29
Figure 2.6 Profile of peramivir standard solution (1 mg/mL)	30
Figure 2.7 Concentration – time profile for low-dose administration on the 1st and 30th day.....	53
Figure 2.8 Concentration – time profile for mid-dose administration on the 1st and 30th day.....	55
Figure 2.9 Concentration – time profile for high-dose administration on the 1st and 30th day.....	57
Figure 2.10 Mean plasma concentration-time curve of peramivir for low-, mid-, high-dose groups on the 1st day after i.v. administration to beagle dogs	58
Figure 2.11 Mean plasma concentration-time curve of peramivir for low-, mid-, high-dose groups on the 30th day after i.v. administration to beagle dogs.....	58
Figure 2.12 Mean plasma concentration-time curve of peramivir for high-dose group on the 1st and 30th day after i.v. administration to beagle dogs.....	62
Figure 2.13 Comparison of AUC _{0-∞} on the 1st and 30th day in different dose groups	62